Monte Rosa Therapeutics, Inc., and Novartis have recently entered into an exclusive global development and commercialization license agreement that aims to advance molecular glue degraders (MGDs), with a particular focus on MRT-6160. This agreement grants Novartis the worldwide rights to develop,
Kapoose Creek Bio, a biotechnology firm well-versed in AI-driven natural product drug discovery, has made a significant leap forward with its latest acquisition. The company has secured an exclusive license to the chemical informatics platform of Adapsyn Bioscience and acquired Adapsyn's drug
In a remarkable advancement in the fight against malaria, The Medicines for Malaria Venture (MMV) and Quotient Sciences have initiated a Phase 1 clinical trial for MMV371, a long-acting injectable (LAI) malaria preventive. Conducted with healthy volunteers in Nottingham, UK, this trial represents a
The intricate relationship between the human microbiome and genetics is garnering significant attention in the scientific community. This interplay is not just about understanding our inner microbial world but also about how these microorganisms influence our genetic makeup and overall health. The
Kivu Biosciences, a San Francisco-based biotechnology startup, has made headlines by raising an impressive $92 million in its Series A funding round. This influx of investment will significantly bolster the company's efforts to advance its groundbreaking antibody-drug conjugates (ADCs), which hold
Rentschler Biopharma, a globally recognized Contract Development and Manufacturing Organization (CDMO), is making significant strides in the biomanufacturing landscape. The company's recent investments showcase its commitment to expanding cGMP capabilities and bolstering cell and gene therapy
